Study Compares HIV Regimens, Notes Less Weight Gain with Doravirine-Based Treatment

A JAMA study found that a once-daily doravirine-based HIV regimen led to less weight gain over 48 weeks compared to a dolutegravir combination, while maintaining similar viral suppression. This randomized clinical trial, conducted in South Africa, is significant as second-generation integrase inhibitors have been linked to substantial weight gain, particularly in women and Black patients.